TMEM217 and acute myeloid leukemia: A Kaplan–Meier analysis also indicated that high expression of TMEM217 was associated with poor prognosis in the TCGA-LAML cohort (Fig. 1E), which was validated in GSE12417-AML, TARGET-AML, and Beat-AML cohorts (Fig. S1G–I), respectively.